Natural History of Paclitaxel-Associated Acute Pain Syndrome: Prospective Cohort Study NCCTG N08C1
Natural History of Paclitaxel-Associated Acute Pain Syndrome: Prospective Cohort Study NCCTG N08C1
复制标题
DOI：
10.1200/jco.2010.33.0308
复制
发表时间：
2011-04-10
影响因子：
45.3
通讯作者：
Lachance, Daniel H.
中科院分区：
文献类型：
--
作者：
Loprinzi, Charles L.;Reeves, Brandi N.;Lachance, Daniel H.
紫杉醇急性疼痛综合征（P-APS）和紫杉醇慢性神经病变的特征和自然史尚未得到很好的描述。（70至90 mg/m2）完成每日问卷和每周欧洲癌症研究和治疗组织（EORTC）化疗诱导的周围神经病变（CIPN）-结果P-APS症状在化疗后第3天达到高峰。20%的患者在第一剂紫杉醇治疗时疼痛评分为5至10分。感觉神经病变症状比运动或自主神经病变症状更突出。在感觉神经病变症状中，麻木和刺痛比刺痛或烧灼痛更突出。与第一剂量的紫杉醇P-APS疼痛评分较高的患者似乎有更多的慢性neuropathy.ConclusionThese数据支持，P-APS是与神经病理学，而不是关节痛和/或myalgias。麻木和刺痛是比刺痛或烧灼痛更突出的慢性神经病症状。
PurposeThe characteristics and natural history of the paclitaxel-acute pain syndrome (P-APS) and paclitaxel's more chronic neuropathy have not been well delineated.MethodsPatients receiving weekly paclitaxel (70 to 90 mg/m(2)) completed daily questionnaires and weekly European Organisation for Research and Treatment of Cancer (EORTC) Chemotherapy-Induced Peripheral Neuropathy (CIPN) -20 instruments during the entire course of therapy.ResultsP-APS symptoms peaked 3 days after chemotherapy. Twenty percent of patients had pain scores of 5 to 10 of 10 with the first dose of paclitaxel. Sensory neuropathy symptoms were more prominent than were motor or autonomic neuropathy symptoms. Of the sensory neuropathy symptoms, numbness and tingling were more prominent than was shooting or burning pain. Patients with higher P-APS pain scores with the first dose of paclitaxel appeared to have more chronic neuropathy.ConclusionThese data support that the P-APS is related to nerve pathology as opposed to being arthralgias and/or myalgias. Numbness and tingling are more prominent chronic neuropathic symptoms than is shooting or burning pain.